Celsion reports positive interim data from Phase 2 DIGNITY Trial of ThermoDox in RCWB
Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox in Recurrent Chest Wall Breast Cancer.
More... |
All times are GMT -7. The time now is 07:30 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021